Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer

Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer

(2010) Marcus Schmidt et al.   BREAST CANCER RESEARCH AND TREATMENT

Clinical Outcomes of Patients With Breast Cancer in a Phase I Clinic: The M. D. Anderson Cancer Center Experience

(2010) Jennifer Wheler et al.   Clinical Breast Cancer

Phase II Study of the Human Anti-Epithelial Cell Adhesion Molecule Antibody Adecatumumab in Prostate Cancer Patients with Increasing Serum Levels of Prostate-Specific Antigen after Radical Prostatectomy

(2010) Norbert Marschner et al.   UROLOGIA INTERNATIONALIS

An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer

(2009) M. Schmidt et al.   ANNALS OF ONCOLOGY

Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975

(2009) C. La Vecchia et al.   ANNALS OF ONCOLOGY

Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases

(2009) Ashley Cimino et al.   BREAST CANCER RESEARCH AND TREATMENT

Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer

(2008) M. Schmidt et al.   CLINICAL CANCER RESEARCH